welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
approved for marketing

The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation

key information

study id #: NCT04337112

condition: Muscular Dystrophy, Duchenne; DMD

status: approved for marketing

purpose:

This is an open label expanded access program for boys, 3 to 12 years old, for the treatment of Duchenne muscular dystrophy (DMD) with confirmed mutation(s) in the dystrophin gene that is amenable to skipping of exon 53.

intervention: Viltolarsen

mechanism of action: Exon-skipping to promote dystrophin production

last updated: August 27, 2020